Schizophrenia remains a significant health problem despite neuroleptic drugs. Many patients are refractory and others experience significant side effects. Social and health service costs are much greater than drug costs, therefore analyses such as the one presented are likely to favour widening the armoury of neuroleptics. Definitive proof of the primacy of a particular neuroleptic requires longer-term trials and follow-up.